70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast CancerFátima Cardoso, Martine Piccart, Laura J. van’t Veer et al.|New England Journal of Medicine|2016Cited by 2k
70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by ageMartine Piccart, Emiel J. Rutgers, Laura van ‘t Veer et al.|The Lancet Oncology|2021Cited by 355
Small Molecule Antagonists of the σ-1 Receptor Cause Selective Release of the Death Program in Tumor and Self-Reliant Cells and Inhibit Tumor Growth <b> <i>in Vitro</i> </b> and <b> <i>in Vivo</i> </b>Barbara A. Spruce, Suzanne A. Eccles, Lorna Campbell et al.|Cancer Research|2004Cited by 165
The EORTC 10041/BIG 03-04 MINDACT trial is feasible: Results of the pilot phaseEmiel J. Rutgers, Fátima Cardoso, Jan Bogaerts et al.|European Journal of Cancer|2011Cited by 105
Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor–Positive Breast CancerPeter Schmid, Alastair M. Thompson|Journal of Clinical Oncology|2016Cited by 96